SD 169 (indole-5-carboxamide): Selective ATP-Competitive p38 MAPK Inhibitor

Executive Summary: SD 169 (indole-5-carboxamide) is a crystalline, high-purity small molecule optimized for selective, ATP-competitive inhibition of p38α and p38β MAP kinases (≥97% purity, APExBIO). It modulates key cellular responses—such as inflammation, T cell activity, apoptosis, and autophagy—by blocking p38 MAPK signaling pathways (Stadnicki et al., 2024). In preclinical models, SD 169 preserved pancreatic beta cell function and improved glucose homeostasis by reducing T cell infiltration [APExBIO Datasheet]. The compound’s dual-action mechanism enhances dephosphorylation of the p38 activation loop, leading to increased inactivation specificity (Stadnicki et al., 2024). SD 169 is validated for workflows in apoptosis assays, axonal regeneration, and type 1 diabetes research. Recent mechanistic advances position SD 169 as a next-generation research tool for kinase-targeted studies [Mechanistic Advances].

Biological Rationale

p38 MAP kinases (particularly p38α and p38β) orchestrate critical cellular processes in response to stressors such as cytokines, UV radiation, and osmotic shock (Stadnicki et al., 2024). Dysregulation of these kinases is implicated in inflammatory diseases, neurodegeneration, and diabetes. Selective inhibition of p38 MAPK signaling modulates the downstream production of pro-inflammatory cytokines and T cell activation, which are central to pathologies like type 1 diabetes and nerve injury. SD 169 (indole-5-carboxamide) enables targeted disruption of these pathways with high specificity and minimal off-target effects [APExBIO Datasheet].

Mechanism of Action of SD 169 (indole-5-carboxamide)

SD 169 is an ATP-competitive inhibitor, binding selectively to the active site of p38α and p38β MAP kinases. X-ray structural studies reveal that SD 169 stabilizes an inactive conformation of the kinase activation loop, exposing the phospho-threonine site for efficient dephosphorylation by PPM phosphatases such as WIP1 (Stadnicki et al., 2024, Fig. 2). This dual-action mechanism both blocks kinase activity and accelerates dephosphorylation, promoting rapid inactivation of p38 signaling. The result is robust suppression of inflammatory cytokine production, regulation of T cell differentiation, and protective effects in models of beta cell destruction and nerve injury.

Evidence & Benchmarks

• SD 169 demonstrated selective, ATP-competitive inhibition of p38α and p38β MAPKs, with minimal activity against unrelated kinases (Stadnicki et al. 2024, DOI).
• In NOD mouse models, SD 169 reduced T cell infiltration into pancreatic islets, preserved beta cell mass, and improved glucose homeostasis (APExBIO, Product Page).
• SD 169 increased the rate of p38α activation loop dephosphorylation by WIP1 phosphatase, as confirmed by in vitro X-ray crystallography and phosphatase assays (Stadnicki et al. 2024, DOI).
• In nerve injury models, SD 169 enhanced Schwann cell signaling and reduced TNF-mediated Schwann cell death, promoting axonal regeneration (APExBIO, Product Page).
• SD 169 exhibits solubility of 1.4 mg/mL in ethanol, 5 mg/mL in DMSO, and 16 mg/mL in dimethylformamide; optimal storage at -20°C maintains stability and purity (APExBIO, Product Page).

For expanded protocol guidance and troubleshooting, see this guide, which provides stepwise methods but does not detail the dual-action mechanism elucidated here.

Applications, Limits & Misconceptions

SD 169 has validated uses in:

• Apoptosis assays: Enables quantifiable assessment of p38 MAPK-dependent cell death pathways [Apoptosis Guide]. This contrasts with the present article, which emphasizes mechanistic and translational insights.
• Type 1 diabetes research: Reduces T cell-driven beta cell loss and preserves insulin production in preclinical models [Translational Strategies]. Here, we integrate recent findings on kinase dephosphorylation dynamics.
• Axonal regeneration: Supports nerve repair through modulation of Schwann cell survival and signaling.
• Inflammatory cytokine modulation: Suppresses downstream targets of p38 MAPK, reducing inflammatory mediators.

Common Pitfalls or Misconceptions

• SD 169 is not a pan-kinase inhibitor; it is highly selective for p38α and p38β isoforms.
• The compound does not inhibit upstream MAPKKs (e.g., MKK3/6) or unrelated MAPK family members.
• SD 169 is not suitable for long-term solution storage; solutions should be freshly prepared due to stability limits at room temperature.
• The efficacy of SD 169 is not established in human clinical trials; all data are preclinical or in vitro.
• SD 169 does not reverse established tissue damage but prevents further injury by modulating signaling cascades.

Workflow Integration & Parameters

SD 169 (indole-5-carboxamide) is supplied by APExBIO as a crystalline solid with a molecular weight of 160.2 g/mol (C9H8N2O; SKU C5850). Purity is guaranteed at ≥97%. For optimal experimental performance, dissolve at up to 1.4 mg/mL in ethanol, 5 mg/mL in DMSO, or 16 mg/mL in DMF. Store at -20°C. Solutions should be used within one week when stored at -20°C and protected from light. For apoptosis and cell-based assays, recommended working concentrations range from 0.1 to 10 μM depending on cell type and endpoint [APExBIO]. Shipping is performed with blue ice for small molecules to ensure cold chain integrity.

To maximize assay reliability, see the workflow tips and troubleshooting strategies in this guide, which details common challenges for apoptosis and pathway modulation studies, complementing the mechanistic focus here.

Conclusion & Outlook

SD 169 (indole-5-carboxamide) offers a robust, selective solution for inhibition of p38α and p38β MAPKs. Its dual mechanism—ATP-competitive binding and facilitation of phosphatase-mediated deactivation—enables precise control of inflammatory signaling and T cell function. These properties support its use in apoptosis assays, type 1 diabetes research, and nerve regeneration models. Ongoing mechanistic advances, such as those presented by Stadnicki et al. (2024), position SD 169 as a next-generation research tool for dissecting MAPK-dependent processes. For detailed protocols and product information, visit the APExBIO SD 169 product page.